The Committee for Medicinal Products for Human Use (CHMP) recommended 2 insulin biosimilars for marketing authorization in Europe.
Europe’s Committee for Medicinal Products for Human Use (CHMP) adopted positive opinions for 2 insulin biosimilars, meaning that the agency has recommended the European Commission (EC) grant them marketing authorization.
The opinions are in reference to Inpremzia, a human insulin biosimilar referencing Actrapid, and Truvelog Mix 30, an insulin aspart biosimilar referencing NovoMix 30. The 2 products mark the fifth and sixth approvals for insulin biosimilars for use in the European Union.
More on Truvelog Mix 30
Truvelog Mix 30 was developed by Sanofi-Aventis and is an extension of the original Truvelog (100 U/mL), which was approved for marketing in Europe in June 2020 and references NovoRapid, also known as Novolog in the United States. NovoMix is a Novolog product that contains 30% insulin aspart, an intermediate- or long-acting insulin, and 70% insulin aspart protamine, a fast-acting insulin.
It takes less than 30 minutes to activate once injected, and the peak action is reached in the first 1 to 4 hours and lasts for less than 24 hours. In some countries, NovoMix 30 is marketed as Novolog Mix. A similar product developed by Mylan IRE Healthcare Limited (Kirsty; formerly known as Kixelle) was approved for marketing authorization in the European Union in February 2021.
If granted marketing authorization from the EC, the substance will be available as a 100-U/mL suspension for injection and is indicated for use in adults, adolescents, and children 10 years or older with type 2 diabetes.
The original Truvelog was also approved by the Australian Therapeutic Goods Administration, the Australian equivalent of the FDA and the European Medicines Agency, in October 2020.
More on Inpremzia
Inpremzia was developed by Baxter Holding and is indicated for the treatment of patients with type 2 diabetes. The biosimilar will be available at a 1-IU/mL solution for infusion. Inpremzia is a fast-acting injectable insulin that lowers blood glucose by allowing for glucose to be absorbed into muscle and fat cells, inhibiting glucose output from the liver.
The originator, Actrapid, was approved for use in the European Union in October 2002. The CHMP based its positive opinion on data comparing Actrapid to Inpremzia that demonstrated similar safety and efficacy profiles between the 2 products. Neutral insulin injections like Actrapid and Inpremzia begin lowering the patient’s blood sugar level about 30 minutes after administration and lasts for approximately 8 hours.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.